A study from the Weizmann Institute of Science’s Immunotherapy Research Center released this week highlights the discovery of a new class of immune-activating molecules that could help the body’s ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. Down the line, Adagene could make up to $840 million in development and commercial ...

Scientists from Duke-NUS Medical School and their collaborators have created one of the most comprehensive single cell maps of the developing human brain. The atlas captures nearly every cell type, ...

CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific ...

A new imaging method that can reveal objects concealed behind opaque materials like sand, fog and human tissue for instance, has been developed by researchers at the Institut Langevin in Paris and TU ...

Asimov launched its AAV Edge Stable Producer system with the goal of addressing the shortcomings of traditional transient transfection-based production and bringing AAV manufacturing standards closer ...

Smartphones have undoubtedly transformed the workplace, but their ubiquity comes with a cost: productivity. Research shows that employees can lose hours each day to personal device use, whether ...

Human cheek cells under a microscope. The skin on our lips is distinctly different and more complex than other skin on our bodies, and primary lip cells are hard to acquire, which holds back basic ...

Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, ...

When you watch “The Matrix” at Cosm, you’re essentially seeing a film within a film. A shot inside an apartment becomes a glimpse into an entire complex. A fight scene on a rooftop is now one small ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...